OTCQX:MRVFF - Post by User
Comment by
alpi1441on Apr 21, 2011 4:59pm
325 Views
Post# 18472251
RE: RE: Transcript: Coviden CEO on numbers... Penn
RE: RE: Transcript: Coviden CEO on numbers... PennAnother quote from the Q&A
Michael Matson - Mizuho Securities USA Inc.
Okay. And then in your branded drug business. I know you kind ofcommented on how you're doing with the new branded drugs, but at whatpoint do you think you're going to see these new branded products startto offset the declines that you're seeing in your old products that haverun off patent?
Richard Meelia
I would say we're starting to see it already just not at the extentthat it would be totally compensate for the loss. And I believe we'retalking in excess of $100 million between RESTORIL and tofranil. And so acouple of years from now, I mean we will see -- I think within 12 to18 months, we'll see that kind of sales volume being generated by EXALGOand PENNSAID and feel pretty comfortable. Those are peak year sales of Ithink PENNSAID was $150 million or so, EXALGO was $200 million in thatcategory.